Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells

• Published in: Biochemical and biophysical research communications 2003-07, Vol.307 (1), p.188-197
• Main Authors: Abdollahi, Abbas, Gruver, Briana N, Patriotis, Christos, Hamilton, Thomas C
• Format: Article
• Language: English
• Subjects: Animals; Cell Size; Cells, Cultured; EGF; Epidermal Growth Factor - metabolism; Epithelial Cells - cytology; Epithelial Cells - physiology; ErbB Receptors - genetics; ErbB Receptors - metabolism; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Microarray; Oligonucleotide Array Sequence Analysis; Ovarian cancer; Ovarian Neoplasms - metabolism; Ovarian surface epithelia; Ovary - cytology; Ovary - physiology; Rats; Signal Transduction - physiology; Tumor Cells, Cultured
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/S0006-291X(03)01140-9

Alteration in epidermal growth factor receptor (EGFR) family signaling is among the most frequently implicated effectors of human oncogenesis. Overexpression of members of this family of receptors has often been detected in many epithelial tumors and is believed to be associated with an overall poor prognosis in patients with cancer. Therefore, we hypothesized that identification of potential EGF target genes in normal cells will provide a basis for unbiased genetic analysis of this signaling pathway in cancer. We utilized Atlas Rat 1.2 nylon cDNA arrays (Clontech) to determine gene expression changes in normal rat ovarian surface epithelial (ROSE) cells following EGF treatment. The results indicate activation of genes involved in a wide variety of cellular mechanisms, including regulation of cell cycle and proliferation, apoptosis, and protein turnover. In addition, using an in vitro model of ovarian cancer, we demonstrated that malignant transformation of ROSE cells resulted in alteration of downstream effectors of the EGFR pathway, as exemplified by aberrant expression of p66Shc, c-Jun, c-Myc, c- Fos, Lot1, p21Cip/Waf, and cdc25A. These data suggest that knowledge of the downstream genetic lesions, which may result in loss of growth factor requirement of the affected cells, will be crucial for the selection of the EGFR pathway as an effective target for cancer therapy.